MARKET

AQST

AQST

Aquestive Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.15
+0.01
+0.19%
After Hours: 5.15 0 0.00% 19:36 06/05 EDT
OPEN
5.20
PREV CLOSE
5.14
HIGH
5.48
LOW
5.08
VOLUME
852.46K
TURNOVER
--
52 WEEK HIGH
10.00
52 WEEK LOW
1.410
MARKET CAP
172.95M
P/E (TTM)
-2.0394
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AQST stock price target is 17.50 with a high estimate of 31.00 and a low estimate of 8.00.

EPS

AQST News

More
Aquestive Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders
GlobeNewswire · 1d ago
Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock Options
Investors need to pay close attention to Aquestive Therapeutics (AQST) stock based on the movements in the options market lately.
Zacks · 05/28 13:42
Why Aquestive Therapeutics (AQST) Stock Might be a Great Pick
Aquestive Therapeutics (AQST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks · 05/27 13:22
96 Biggest Movers From Yesterday
Gainers Mmtec, Inc. (NASDAQ: MTC) shares climbed 86.4% to close at $2.05 on Tuesday after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019.
Benzinga · 05/27 08:20
PANW, SPLK among premarket gainers
Seeking Alpha - Article · 05/22 13:12
HC Wainwright & Co. Maintains Buy on Aquestive Therapeutics, Raises Price Target to $15
HC Wainwright & Co. maintains Aquestive Therapeutics (NASDAQ:AQST) with a Buy and raises the price target from $13 to $15.
Benzinga · 05/22 11:01
Aquestive Press Release Confirms Advancement Of Royalty Monetization Plan As Sunovion Pharma's Apomorphine Sublingual Film Therapy Receives FDA Approval
Benzinga · 05/21 21:29
Aquestive Therapeutics Advances Royalty Monetization Plan as Sunovion Pharmaceuticals’ Apomorphine Sublingual Film Therapy Receives FDA Approval
Aquestive Therapeutics, Inc. (AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced plans to advance its strategy to monetize the ant
GlobeNewswire · 05/21 21:27

Industry

Pharmaceuticals
+0.57%
Pharmaceuticals & Medical Research
+0.37%

Hot Stocks

Symbol
Price
%Change

About AQST

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
More

Webull offers kinds of Aquestive Therapeutics Inc stock information, including NASDAQ:AQST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AQST stock news, and many more online research tools to help you make informed decisions.